CDK4 inhibition diminishes p53 activation by MDM2 antagonists

Anusha Sriraman, Antje Dickmanns, Zeynab Najafova, Steven Johnsen, Matthias Dobbelstein

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The genes encoding MDM2 and CDK4 are frequently co-amplified in sarcomas, and inhibitors to both targets are approved or clinically tested for therapy. However, we show that inhibitors of MDM2 and CDK4 antagonize each other in their cytotoxicity towards sarcoma cells. CDK4 inhibition attenuates the induction of p53-responsive genes upon MDM2 inhibition. Moreover, the p53 response was also attenuated when co-depleting MDM2 and CDK4 with siRNA, compared to MDM2 single knockdown. The complexes of p53 and MDM2, as well as CDK4 and Cyclin D1, physically associated with each other, suggesting direct regulation of p53 by CDK4. Interestingly, CDK4 inhibition did not reduce p53 binding or histone acetylation at promoters, but rather attenuated the subsequent recruitment of RNA Polymerase II. Taken together, our results suggest that caution must be used when considering combined CDK4 and MDM2 inhibition for patient treatment. Moreover, they uncover a hitherto unknown role for CDK4 and Cyclin D1 in sustaining p53 activity.

Original languageEnglish (US)
Article number918
JournalCell Death and Disease
Volume9
Issue number9
DOIs
StatePublished - Sep 1 2018
Externally publishedYes

Fingerprint

Cyclin D1
Sarcoma
RNA Polymerase II
p53 Genes
Acetylation
Histones
Small Interfering RNA
Therapeutics
Genes

ASJC Scopus subject areas

  • Immunology
  • Cellular and Molecular Neuroscience
  • Cell Biology
  • Cancer Research

Cite this

CDK4 inhibition diminishes p53 activation by MDM2 antagonists. / Sriraman, Anusha; Dickmanns, Antje; Najafova, Zeynab; Johnsen, Steven; Dobbelstein, Matthias.

In: Cell Death and Disease, Vol. 9, No. 9, 918, 01.09.2018.

Research output: Contribution to journalArticle

Sriraman, Anusha ; Dickmanns, Antje ; Najafova, Zeynab ; Johnsen, Steven ; Dobbelstein, Matthias. / CDK4 inhibition diminishes p53 activation by MDM2 antagonists. In: Cell Death and Disease. 2018 ; Vol. 9, No. 9.
@article{969a9d59e3884408a7e9611fe83edfcc,
title = "CDK4 inhibition diminishes p53 activation by MDM2 antagonists",
abstract = "The genes encoding MDM2 and CDK4 are frequently co-amplified in sarcomas, and inhibitors to both targets are approved or clinically tested for therapy. However, we show that inhibitors of MDM2 and CDK4 antagonize each other in their cytotoxicity towards sarcoma cells. CDK4 inhibition attenuates the induction of p53-responsive genes upon MDM2 inhibition. Moreover, the p53 response was also attenuated when co-depleting MDM2 and CDK4 with siRNA, compared to MDM2 single knockdown. The complexes of p53 and MDM2, as well as CDK4 and Cyclin D1, physically associated with each other, suggesting direct regulation of p53 by CDK4. Interestingly, CDK4 inhibition did not reduce p53 binding or histone acetylation at promoters, but rather attenuated the subsequent recruitment of RNA Polymerase II. Taken together, our results suggest that caution must be used when considering combined CDK4 and MDM2 inhibition for patient treatment. Moreover, they uncover a hitherto unknown role for CDK4 and Cyclin D1 in sustaining p53 activity.",
author = "Anusha Sriraman and Antje Dickmanns and Zeynab Najafova and Steven Johnsen and Matthias Dobbelstein",
year = "2018",
month = "9",
day = "1",
doi = "10.1038/s41419-018-0968-0",
language = "English (US)",
volume = "9",
journal = "Cell Death and Disease",
issn = "2041-4889",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - CDK4 inhibition diminishes p53 activation by MDM2 antagonists

AU - Sriraman, Anusha

AU - Dickmanns, Antje

AU - Najafova, Zeynab

AU - Johnsen, Steven

AU - Dobbelstein, Matthias

PY - 2018/9/1

Y1 - 2018/9/1

N2 - The genes encoding MDM2 and CDK4 are frequently co-amplified in sarcomas, and inhibitors to both targets are approved or clinically tested for therapy. However, we show that inhibitors of MDM2 and CDK4 antagonize each other in their cytotoxicity towards sarcoma cells. CDK4 inhibition attenuates the induction of p53-responsive genes upon MDM2 inhibition. Moreover, the p53 response was also attenuated when co-depleting MDM2 and CDK4 with siRNA, compared to MDM2 single knockdown. The complexes of p53 and MDM2, as well as CDK4 and Cyclin D1, physically associated with each other, suggesting direct regulation of p53 by CDK4. Interestingly, CDK4 inhibition did not reduce p53 binding or histone acetylation at promoters, but rather attenuated the subsequent recruitment of RNA Polymerase II. Taken together, our results suggest that caution must be used when considering combined CDK4 and MDM2 inhibition for patient treatment. Moreover, they uncover a hitherto unknown role for CDK4 and Cyclin D1 in sustaining p53 activity.

AB - The genes encoding MDM2 and CDK4 are frequently co-amplified in sarcomas, and inhibitors to both targets are approved or clinically tested for therapy. However, we show that inhibitors of MDM2 and CDK4 antagonize each other in their cytotoxicity towards sarcoma cells. CDK4 inhibition attenuates the induction of p53-responsive genes upon MDM2 inhibition. Moreover, the p53 response was also attenuated when co-depleting MDM2 and CDK4 with siRNA, compared to MDM2 single knockdown. The complexes of p53 and MDM2, as well as CDK4 and Cyclin D1, physically associated with each other, suggesting direct regulation of p53 by CDK4. Interestingly, CDK4 inhibition did not reduce p53 binding or histone acetylation at promoters, but rather attenuated the subsequent recruitment of RNA Polymerase II. Taken together, our results suggest that caution must be used when considering combined CDK4 and MDM2 inhibition for patient treatment. Moreover, they uncover a hitherto unknown role for CDK4 and Cyclin D1 in sustaining p53 activity.

UR - http://www.scopus.com/inward/record.url?scp=85053180024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053180024&partnerID=8YFLogxK

U2 - 10.1038/s41419-018-0968-0

DO - 10.1038/s41419-018-0968-0

M3 - Article

C2 - 30206211

AN - SCOPUS:85053180024

VL - 9

JO - Cell Death and Disease

JF - Cell Death and Disease

SN - 2041-4889

IS - 9

M1 - 918

ER -